Personalized medicine has emerged as a significant breakthrough in medical research, offering tailored treatments based on an individual’s genetic information. This approach has gained immense importance for patients, doctors, and pharmaceutical firms alike. However, a recent study by Professor Saurabh Mishra from George Mason University School of Business raises concerns about the potential diminishing returns for companies heavily invested in personalized medicine.
Analyzing data from 149 firms between 2007 and 2017, Mishra’s research found that the optimal representation of personalized medicine within a pharmaceutical company’s portfolio was around 30%. Companies with a significantly higher or lower proportion faced penalties in the financial markets, experiencing lower returns and higher risks on their investments.
Continue reading… “Managing the Transition: Balancing Risks and Returns in Personalized Medicine”
